Keyword: Hikma Pharmaceuticals
Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.
Hikma's U.S. unit West-Ward boosted prices as much as fourfold on a half-dozen generic meds, most of them liquid formulations.
The FDA has already nixed two generics of GSK's Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.
GlaxoSmithKline dodged yet another generic Advair bullet. Hikma and Vectura's knockoff was struck down at FDA Thursday, and an approval later this year is a long shot, the companies say.
Pfizer, drug wholesaling giant McKesson, and others are trying to keep Arkansas from using their drugs in its effort to perform seven executions in short order.
Mylan execs were confident of a generic Advair approval just weeks ago, but on Wednesday got a "no-go" from the FDA. Now the question is how much it'll hurt.
Thanks to some crafty payer negotiating from GSK, even if Advair generics win approval, it may be a while before they gain serious traction, even if it wins approval on time.
Jordan-based Hikma is expanding the manufacturing and distribution operations at a large manufacturing site it picked up in 2015 from Boehringer Ingelheim.
GlaxoSmithKline isn’t looking forward to generics of its respiratory behemoth, Advair. But third-to-the-party Sandoz isn’t, either--and it’s the one that’s doing its best to trip them up.
Respiratory player Vectura can set aside its hopes of snagging a COPD indication for ICS/LABA med Flutiform--at least, for now.